Focusing on IVDs can save more lives and billions in costs
With increased focus on improving the quality, efficacy, and cost-effectiveness of lab tests, the IVD industry can drive great value for patients and the economics of the healthcare system.
Learning from failure: What Theranos, Interleukin Genetics, & Courtagen can teach us about IVDs
Realistic expectations are essential when forecasting both the adoption of the device and the length of time needed for payers to reimburse for the test to ensure adequate working capital, writes Harry Glorikian.
The Power of Real World Data to Study Women’s Health at Scale
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!